Massive transfusion protocolMANAGEMENT

HEMATOLOGIC AND ONCOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

541 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Acute chest syndrome Acute Hemolytic Transfusion Reaction Anticoagulant reversal (warfarin, DOAC, heparin)Aplastic Anemia (Crisis)Autoimmune Hemolytic Anemia CAR-T and cytokine release syndrome Coagulopathy Delayed Hemolytic Transfusion Reaction Disseminated Intravascular Coagulation (DIC)Essential Thrombocythemia Febrile Non-hemolytic Transfusion Reaction Graft Versus Host Disease (Acute)Hemolytic Uremic Syndrome (HUS)Hemophilia A (Bleeding Crisis)Heparin-Induced Thrombocytopenia (HIT)Hyperviscosity syndrome Immune checkpoint inhibitor toxicity Immune Thrombocytopenic Purpura (ITP)Leukemoid Reaction Leukostasis Massive transfusion protocol Myelofibrosis Neutropenic enterocolitis (typhlitis)Paroxysmal Nocturnal Hemoglobinuria Polycythemia Vera (Crisis)Pure Red Cell Aplasia Sickle Cell (Acute Chest Syndrome)Sickle Cell (Splenic Sequestration)Sickle cell crisis (vaso-occlusive)Symptomatic anemia Thrombocytopenia (severe)Thrombotic Thrombocytopenic Purpura (TTP)Transfusion-Associated Circulatory Overload (TACO)Transfusion-Related Acute Lung Injury (TRALI)Tumor lysis syndrome Von Willebrand Disease (Bleeding)

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp82

Activation criteria and triggers

›Massive transfusion protocol activation

›Physiologic triggers

›Systolic blood pressure 90 mmHg or less on arrival

›Heart rate 120 beats per minute or greater on arrival

›Base deficit 6 mEq/L or worse

›Lactate greater than 4 mmol/L

›Temperature less than 35.0 C on arrival

›Assessment of Blood Consumption score

›Penetrating mechanism

›Positive FAST

›Arrival systolic blood pressure 90 mmHg or less

›Arrival heart rate 120 beats per minute or greater

›2 or more of 4 criteria predicts massive transfusion need

›Shock index

›Heart rate divided by systolic blood pressure

›Shock index greater than 1 as high risk marker for massive transfusion need

›Critical administration threshold

›3 or more units of PRBC transfused in any 1 hour

›Detects ongoing need earlier than the traditional 24 hour definition

›Traditional definition for reference

›10 or more units of PRBC in 24 hours

›Retrospective definition, not useful for real time activation decisions

›Common activation errors

›Under-activation

›Waiting for confirmed laboratory coagulopathy before activating

›Relying on a single normal early vital sign to defer activation

›Late activation

›Sequential single unit ordering instead of protocol activation

›Delay while awaiting crossmatch before giving uncrossmatched blood

›Consequence of delayed activation

›Established lethal triad before balanced products arrive

›Higher crystalloid exposure while awaiting blood

Immediate stabilization bundle

›First minutes bundle

›Airway and breathing

›Airway protection if depressed mental status from shock

›Supplemental oxygen to SpO2 94% or greater

›Circulatory access

›2 large bore IVs, 16 gauge or larger

›Intraosseous access if IV delay

›Rapid infuser or level 1 device activation

›Hemorrhage control maneuvers

›Direct pressure on compressible sites

›Tourniquet for exsanguinating extremity hemorrhage

›Pelvic binder for suspected pelvic fracture

›Warming

›Fluid and blood warmer in line for all resuscitation fluids

›Active external warming with forced air device

›Warm ambient room and remove wet clothing

›Monitoring

›Continuous ECG

›Noninvasive blood pressure every 3 to 5 minutes until stable

›Arterial line for continuous pressure monitoring once feasible

Key concepts and pitfalls

›Core concepts

›Massive transfusion protocol definition

›Predefined, protocolized delivery of balanced blood components in fixed ratio for life threatening hemorrhage

›Designed to bypass sequential single unit ordering delays

›Damage control resuscitation principle

›Blood product predominant resuscitation over crystalloid

›Permissive hypotension paired with rapid hemorrhage control

›Early correction of hypothermia, acidosis, and coagulopathy

›Pitfalls

›Treating the transfusion as the definitive therapy

›Hemorrhage source control is the definitive therapy, transfusion is a bridge

›Crystalloid-heavy resuscitation before blood arrives

›Dilutes clotting factors

›Displaces clot with rising pressure before source control

›Forgetting calcium

›Most commonly omitted element of massive transfusion protocols

›Citrate driven hypocalcemia worsens coagulopathy and cardiac function

Termination and decision points

›Termination criteria

›Hemorrhage source controlled

›Surgical, endoscopic, or angiographic hemostasis achieved

›Physiologic normalization sustained

›Declining transfusion requirement over 1 to 2 hours

›Lactate clearing and base deficit resolving

›Normothermia and correcting coagulopathy on repeat testing

›Reassessment interval

›Team lead reassesses ongoing need every 30 minutes during active protocol

›Futility discussion

›Ongoing exsanguination despite maximal resuscitation with nonsurvivable injury

›Multidisciplinary discussion involving trauma or surgical lead

›Not a unilateral decision by a single team member

02History/hx36

Presentation and mechanism

›Hemorrhage context

›Mechanism of injury

›Blunt versus penetrating trauma

›High energy transfer mechanism

›Non-traumatic hemorrhage context

›Hematemesis or melena

›Postpartum or antepartum bleeding

›Abdominal pain with syncope suggesting ruptured aneurysm or ectopic pregnancy

›Estimated blood loss

›Prehospital blood loss estimate

›Prehospital blood products already administered

Risk factors and context

›Bleeding risk amplifiers

›Anticoagulant use

›Warfarin

›Direct oral anticoagulant

›Antiplatelet use

›Aspirin

›P2Y12 inhibitor

›Known bleeding disorder

›Hemophilia

›Von Willebrand disease

›Liver disease

›Cirrhosis with baseline coagulopathy

›Portal hypertension and variceal risk

›Obstetric risk context

›Current pregnancy or recent delivery

03Physical Exam/exam44

Hemodynamic and perfusion findings

›Shock assessment

›Hypotension

›Systolic blood pressure 90 mmHg or less

›Tachycardia

›Heart rate 120 beats per minute or greater

›Peripheral perfusion

›Cool clammy extremities

›Delayed capillary refill

›Mental status

›Agitation or confusion from cerebral hypoperfusion

›Depressed consciousness in profound shock

Source localization exam

›Trauma source exam

›Chest

›Diminished breath sounds suggesting hemothorax

›Penetrating wound trajectory

›Abdomen and pelvis

›Distension or peritonitis

›Pelvic instability on gentle single compression

›Extremities

›Active external hemorrhage

›Deformity concerning for long bone fracture

›Non-traumatic source exam

›Gastrointestinal

›Hematemesis or melena on exam

›Rectal exam findings

›Obstetric and pelvic

04Differential Diagnosis/ddx32

Sources of massive hemorrhage

›Traumatic sources

›Solid organ injury

›Liver or spleen laceration

›Pelvic fracture with retroperitoneal hemorrhage

›Long bone fracture, especially femur

›Hemothorax

›Major vascular injury

›Non-traumatic sources

›Upper or lower gastrointestinal hemorrhage

›Ruptured abdominal aortic aneurysm

›ICD-10 I71.3 ruptured abdominal aortic aneurysm

›Ruptured ectopic pregnancy

›Postpartum hemorrhage

›ICD-10 O72.1 postpartum hemorrhage

›Disseminated intravascular coagulation with diffuse bleeding

›ICD-10 D65 disseminated intravascular coagulation

›Post-procedural or post-surgical hemorrhage

Shock mimics and non-hemorrhagic causes

›Mimics presenting with similar instability

›Tension pneumothorax

›Obstructive shock, not volume responsive

›Cardiac tamponade

›Obstructive shock, not volume responsive

›Cardiogenic shock

›Pump failure without ongoing blood loss

›Neurogenic shock

›Bradycardia with hypotension after spinal cord injury

05Laboratory Tests/lt48

Baseline hemorrhage labs

›Initial hemorrhage panel

›Complete blood count

›Hemoglobin may be normal early despite major hemorrhage

›Platelet count trend

›Type and crossmatch

›Send immediately, do not delay uncrossmatched transfusion for results

›Conventional coagulation studies

›PT and INR

›INR 1.5 or greater indicates significant coagulopathy

›aPTT

›Fibrinogen

›Target 2 g/L or greater

›Earliest factor to fall critically low in major hemorrhage

›Pitfall of conventional coagulation studies

›Turnaround time 30 to 60 minutes or longer

›Reflects only clot initiation, not clot strength or fibrinolysis

›Poorly predicts real time bleeding risk during active hemorrhage

Viscoelastic and point of care testing

›Viscoelastic testing

›Thromboelastography or rotational thromboelastometry

›Bedside turnaround in minutes

›Assesses clot initiation, clot strength, and fibrinolysis in one test

›Parameter to product mapping

›Prolonged clotting time or R-time

›Guides plasma administration

›Reduced clot amplitude or angle

›Guides cryoprecipitate or fibrinogen concentrate

06Diagnostic Tests/dt40

Scoring Systems

›Massive transfusion prediction tools

›Assessment of Blood Consumption score

›4 components, 2 or more predicts need for massive transfusion

›Simple bedside tool without laboratory delay

›Trauma Associated Severe Hemorrhage score

›Incorporates hemoglobin, base excess, heart rate, systolic blood pressure, FAST result, pelvic fracture, and sex

›More granular but slower to calculate than ABC score

›Shock index

›Heart rate divided by systolic blood pressure

›Shock index greater than 1 as high risk marker

MRI

›MRI role

›Minimal role in acute massive hemorrhage

›Time sensitivity of active hemorrhage precludes MRI

›Instability and incompatible monitoring equipment limitations

›Delayed role

›Selected stable post-resuscitation imaging for specific injury characterization

›CT-based evaluation

›Whole body CT with contrast

›Indications

›Blunt trauma with suspected multi-cavity source once transiently or fully responsive to resuscitation

›Protocol pearls

›Arterial phase for active extravasation

›Portal venous phase for solid organ injury grading

›Interpretation pearls

›Active extravasation as target for angioembolization

07Disposition/dispo14

Level of care criteria

›Operating room and procedural activation

›Immediate operating room for uncontrolled hemorrhage with instability

›Interventional radiology for identified arterial extravasation in a patient stable enough for transport

›Endoscopy activation for gastrointestinal source

›ICU admission criteria

›Ongoing transfusion requirement after initial source control

›Vasopressor requirement

›Mechanical ventilation requirement

Transfer criteria

›Higher-level care transfer

›Facility without massive transfusion protocol or sufficient blood bank inventory

›Early transfer coordination before full exsanguination

›Continue protocol resuscitation during transport

›Need for angioembolization, trauma surgery, or subspecialty surgery unavailable locally

›Pediatric massive hemorrhage without pediatric trauma or blood bank capability

08Treatment/t135

Activation and component ratio strategy

›Balanced component transfusion

›1:1:1 ratio of PRBC to plasma to platelets

›Based on PROPPR trial comparing 1:1:1 to 1:1:2 ratio

›1:1:1 associated with more patients achieving hemostasis and fewer deaths from exsanguination in the first 24 hours

›No significant difference in overall 24 hour or 30 day mortality between ratios

›Early empiric ratio before laboratory results available

›Cooler or pack based delivery to avoid sequential single unit delay

›Early cryoprecipitate consideration

›Fibrinogen falls earliest among clotting factors in major hemorrhage

›Target fibrinogen 2 g/L or greater

›Crystalloid minimization

›Limit crystalloid before blood products available

›Balanced crystalloid preferred over normal saline if crystalloid required

›Excess crystalloid dilutes clotting factors and worsens acidosis

Tranexamic acid

›Tranexamic acid dosing

›Loading dose 1 g IV over 10 minutes

›Maintenance dose 1 g IV over 8 hours

›Time window

›Greatest benefit within 3 hours of injury or bleeding onset

›Beyond 3 hours, no mortality benefit and increased risk of death from bleeding

›Do not administer beyond the 3 hour window

›Administration timing

›Give as soon as massive hemorrhage is recognized

›Do not delay administration while awaiting blood products to arrive

›Evidence anchor

›CRASH-2 trial, reduced death due to bleeding in trauma with early administration

›Class I recommendation for trauma hemorrhage within the time window

Calcium replacement and monitoring

›Citrate-related hypocalcemia

›Mechanism

›Citrate anticoagulant in stored blood products chelates ionized calcium

›Hepatic metabolism of citrate overwhelmed by rapid transfusion rate

›Consequences if untreated

›Worsening coagulopathy, calcium is a required cofactor in the clotting cascade

›Cardiac dysfunction, decreased contractility and arrhythmia risk

›Calcium replacement dosing

›Calcium chloride IV

›1 g IV, preferably through central access or a well-functioning large peripheral line

›Repeat empirically after every 4 units of blood product during rapid transfusion

›Repeat dosing guided by ionized calcium when results available

›Calcium gluconate IV as peripheral alternative

›1 to 2 g IV, roughly one third the elemental calcium of an equal dose of calcium chloride

›Slower onset than calcium chloride

›Monitoring

›Ionized calcium every 30 to 60 minutes during active massive transfusion

›Target ionized calcium 1.1 mmol/L or greater

›Continuous ECG for QT prolongation during replacement

Lethal triad management

›Hypothermia prevention and treatment

›Warm all resuscitation fluids and blood products through an inline fluid warmer

›Active external warming with forced air device

›Target temperature 36.0 C or greater

›Acidosis management

›Address by hemorrhage control and perfusion restoration, not by bicarbonate alone

›Minimize large volume unbalanced crystalloid to avoid hyperchloremic acidosis

›Coagulopathy management

›Balanced component transfusion as primary correction

›Calcium replacement as above

›Reassess with viscoelastic testing or conventional coagulation studies

Permissive hypotension and hemodynamic targets

›Permissive hypotension

›Systolic blood pressure target 80 to 90 mmHg

›Applies during active uncontrolled hemorrhage without traumatic brain injury

›Maintained until surgical or procedural hemorrhage control achieved

›Rationale

›Higher pressure before source control can dislodge early clot

›Avoids further dilution of clotting factors from excess resuscitation volume

›Traumatic brain injury exception

›Permissive hypotension does not apply with traumatic brain injury

›Systolic blood pressure target 100 mmHg or greater, 110 mmHg or greater for age under 50 or over 69, per Brain Trauma Foundation guidance

›Hypotension in traumatic brain injury is independently associated with higher mortality

›Spinal cord injury exception

›Mean arterial pressure target 85 to 90 mmHg to support spinal cord perfusion

›Post source control target

›Mean arterial pressure 65 mmHg or greater once hemorrhage is controlled

Viscoelastic-guided component therapy

›Goal-directed transfusion

›Transition from fixed ratio to viscoelastic-guided therapy once results available

›Reduces unnecessary plasma and platelet exposure once bleeding trend clarifies

›Persistent empiric ratio if viscoelastic testing unavailable

›Continue 1:1:1 ratio and conventional coagulation studies

›Therapy not working troubleshooting

›Reassess for uncontrolled surgical or anatomic bleeding source

›Ongoing large volume requirement despite balanced ratio suggests inadequate source control, not inadequate transfusion

›Reassess for undertreated hypothermia

›Recheck core temperature, escalate warming

›Reassess for undertreated hypocalcemia

›Recheck ionized calcium, escalate calcium dosing frequency

›Reassess for hyperfibrinolysis

›Elevated LY30 on viscoelastic testing despite tranexamic acid

›Confirm tranexamic acid was given and within window

›Escalate to next tier

›Fibrinogen concentrate or additional cryoprecipitate if fibrinogen remains low

›Recombinant factor VIIa as last resort per institutional protocol when standard measures fail

Anticoagulation reversal and uncrossmatched blood

›Anticoagulation reversal in parallel with activation

›Warfarin

›4-factor prothrombin complex concentrate, dosed per INR and product labeling

›Vitamin K 10 mg IV

›Direct oral anticoagulant, factor Xa inhibitor

›Andexanet alfa where available

›4-factor prothrombin complex concentrate if specific antidote unavailable

›Dabigatran

›Idarucizumab 5 g IV

›Reversal does not replace source control or component transfusion

›Uncrossmatched blood

›Emergency release O negative PRBC for women of childbearing potential

›Emergency release O positive PRBC acceptable for males and postmenopausal women when O negative supply limited

›Hazards

›Alloimmunization risk with repeated uncrossmatched exposure

›Rh sensitization risk in Rh-negative women of childbearing potential given Rh-positive product

›Rh immunoglobulin indicated if Rh-negative and received Rh-positive product

›Delayed hemolytic reaction risk from undetected alloantibody

›Transition to type-specific then crossmatched product as soon as available without interrupting resuscitation

Iatrogenic harms of routine ED interventions

›Intubation

›Positive pressure ventilation reduces venous return and can precipitate cardiovascular collapse in hemorrhagic shock

›Resuscitate before induction when feasible, have blood products immediately available at intubation

›Sedation and induction agents

›Standard induction doses can cause profound hypotension in hemorrhagic shock

›Reduced induction dose with hemodynamically neutral agent preferred

›Fluid loading

›Large volume unwarmed crystalloid worsens dilutional coagulopathy, hypothermia, and acidosis

›Blood product predominant resuscitation preferred over crystalloid loading

›Oxygen

›Routine high flow oxygen in a non-hypoxemic patient does not correct hemorrhagic shock and is not a substitute for hemorrhage control

›Vasopressors

›Not first line, do not correct the underlying volume deficit

›Increase afterload without restoring intravascular volume and can mask ongoing blood loss with a falsely reassuring blood pressure

›Reserve for refractory hypotension despite ongoing balanced transfusion, as a bridge to definitive source control

›Mechanical circulatory support

›Intra-aortic balloon pump is contraindicated in uncontrolled hemorrhagic shock

›Augments afterload and can worsen bleeding, does not address volume loss

›Anticoagulation

›Empiric anticoagulation contraindicated during active massive hemorrhage

›Prior therapeutic anticoagulation requires reversal, not continuation

›Fibrinolysis

›Systemic fibrinolytic therapy is contraindicated in active massive hemorrhage

›Analgesia

›Standard opioid doses can worsen hypotension in hemorrhagic shock

›Reduced titrated dose with close hemodynamic monitoring preferred

09Special Populations/sp40

Pregnancy

›Obstetric hemorrhage integration

›Physiologic considerations

›Blood volume expanded 30 to 50 percent, shock signs delayed until 30 to 40 percent blood loss

›Left lateral tilt or manual uterine displacement to relieve aortocaval compression during resuscitation

›Fibrinogen priority

›Fibrinogen falls earlier and more severely in obstetric hemorrhage than in trauma

›Early cryoprecipitate, target fibrinogen 2 g/L or greater

›Rh status

›Rh immunoglobulin if Rh-negative and received Rh-positive uncrossmatched product

›Medication cautions carried from Treatment

›Tranexamic acid dosing and time window unchanged in pregnancy and postpartum hemorrhage

›Andexanet alfa and 4-factor prothrombin complex concentrate use individualized with obstetric and hematology input

Geriatric

›Older adult considerations

›Blunted physiologic response

›Beta blocker use can mask expected tachycardia

›Chronic hypertension raises the effective hypotension threshold, individualize permissive hypotension target

›Higher anticoagulant and antiplatelet exposure

›Lower threshold for early reversal agent administration

›Lower physiologic reserve

›Earlier decompensation for a given blood loss volume

›Lower threshold for ICU level monitoring

Pediatrics

›Pediatric massive transfusion

›Weight-based component dosing

›PRBC 10 to 15 mL/kg per aliquot

›Verify against current pediatric guideline before use

10Background/b32

Epidemiology

›Epidemiologic overview

›Hemorrhage as the leading cause of preventable death after injury

›Accounts for roughly a third of trauma deaths

›Massive transfusion frequency

›Required in roughly 3 to 5 percent of trauma patients receiving any transfusion

›Outcomes

›Mortality among patients requiring massive transfusion remains high, commonly cited in the range of 20 to 50 percent depending on population and injury severity

Pathophysiology

›Trauma-induced coagulopathy

›Early endogenous coagulopathy

›Tissue injury and shock activate the thrombomodulin-protein C pathway

›Leads to inactivation of factors Va and VIIIa and hyperfibrinolysis

›Present on arrival before any resuscitation fluid is given

›Iatrogenic dilutional coagulopathy

›Superimposed on endogenous coagulopathy by crystalloid and unbalanced transfusion

›Lethal triad

›Hypothermia

›Impairs enzymatic clotting cascade function and platelet function

›Acidosis

›Impairs clotting factor activity

›Coagulopathy

›Each element amplifies the other two in a self-reinforcing cycle

Therapeutic Considerations

›Damage control resuscitation rationale

›Balanced ratio transfusion

›Approximates whole blood composition and limits dilutional coagulopathy

›Permissive hypotension

11Patient Discharge Instructions/pdi18

copy discharge instructions

›Discharge instructions after hospitalization involving massive transfusion

›Diagnosis and course explanation

›Large volume blood product transfusion was required to treat major bleeding

›Expected recovery

›Fatigue and reduced exercise tolerance while anemia resolves

›Anemia follow-up bloodwork as arranged

›Medication instructions

›Acetaminophen 500 to 1000 mg by mouth every 6 hours as needed for pain or fever, maximum 3000 mg per day

›Iron supplementation if prescribed for post-hemorrhage anemia

›Resume or hold anticoagulation only per the treating team's explicit instruction

›Return immediately for

›Fever, jaundice, or dark urine in the 2 to 10 days after transfusion, suggesting a delayed transfusion reaction

›Recurrent bleeding from the original site

›Chest pain or shortness of breath

›Fainting or near-fainting

›Follow-up plan

›Primary care or surgical follow-up within 1 to 2 weeks

›Repeat hemoglobin check per treating team instruction

12References/r20

Guidelines and key trials

›Core guidelines

›Advanced Trauma Life Support, American College of Surgeons Committee on Trauma

›Damage control resuscitation framework

›European guideline on management of major bleeding and coagulopathy following trauma

›Balanced ratio and tranexamic acid recommendations

›Eastern Association for the Surgery of Trauma practice management guideline for damage control resuscitation

›Landmark trials

›PROPPR trial

›Compared 1:1:1 to 1:1:2 ratio of PRBC to plasma to platelets

›More patients achieved hemostasis and fewer died from exsanguination in the first 24 hours with 1:1:1

›CRASH-2 trial

›Tranexamic acid reduced death due to bleeding in trauma when given early

›No benefit and possible harm when given beyond 3 hours from injury

›CRASH-3 trial

›Tranexamic acid in traumatic brain injury, benefit concentrated in mild to moderate injury given early

Coding and terminology

›Coding references

›ICD-10 R57.1 hypovolemic shock

›ICD-10 T79.4XXA traumatic shock, initial encounter

›ICD-10 D65 disseminated intravascular coagulation

›ICD-10 O72.1 postpartum hemorrhage

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed September 13, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.